Get the Stockscreener App
4.75
24.60%
-1.55
Biodexa Pharmaceuticals Plc Adr stock is traded at $4.75, with a volume of 452.81K.
It is down -24.60% in the last 24 hours and down -11.55% over the past month.
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
See More
Previous Close:
$6.30
Open:
$5.82
24h Volume:
452.81K
Relative Volume:
0.68
Market Cap:
$2.94M
Revenue:
$644.60K
Net Income/Loss:
$-9.87M
P/E Ratio:
-0.00567
EPS:
-837.9618
Net Cash Flow:
$-9.02M
1W Performance:
-5.75%
1M Performance:
-11.55%
6M Performance:
-56.82%
1Y Performance:
-89.28%
1-Day Range:
$4.73
$6.29
1-Week Range:
$4.00
$8.94
52-Week Range:
$3.58
$92.00
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Company Profile
Name
Biodexa Pharmaceuticals Plc Adr
Sector
Industry
Phone
-
Address
-
Compare BDRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BDRX
Biodexa Pharmaceuticals Plc Adr
|
4.75 | 3.90M | 644.60K | -9.87M | -9.02M | -837.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-08-24 | Initiated | Ladenburg Thalmann | Buy |
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Latest News
Biodexa Pharmaceuticals (NASDAQ:BDRX) Shares Down 53.8% – Time to Sell? - Defense World
Biodexa Pharmaceuticals (NASDAQ: BDRX) Stock on December 10, 2025: Violent Rally, Phase 3 FAP Progress and What 2026 Might Hold - ts2.tech
Wall Street analysts’ outlook for Biodexa Pharmaceuticals Plc ADR (BDRX) - setenews.com
Biodexa enrolls first European patients in phase 3 FAP trial By Investing.com - Investing.com South Africa
Biodexa enrolls first European patients in phase 3 FAP trial - Investing.com
EBIT per share of Biodexa Pharmaceuticals plc Sponsored ADR – FWB:5MP - TradingView
[424B3] Biodexa Pharmaceuticals Plc Prospectus Filed Pursuant to Rule 424(b)(3) - Stock Titan
Biodexa activates first European site for phase 3 FAP trial By Investing.com - Investing.com India
Biodexa activates first European site for phase 3 FAP trial - Investing.com
Biodexa Pharmaceuticals plc (BDRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Biodexa Pharmaceuticals (NASDAQ:BDRX) Stock Price Down 0.4% – What’s Next? - Defense World
[POS AM] Biodexa Pharmaceuticals Plc SEC Filing - Stock Titan
Total debt per share of Biodexa Pharmaceuticals plc Sponsored ADR – BER:5MP - TradingView
What Makes Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) a New Buy Stock - MSN
Holdings of Biodexa Pharmaceuticals Plc ADR (BDRX) are aligned with the stars - setenews.com
Biodexa receives EMA approval for phase 3 FAP treatment trial - Investing.com India
Biodexa (NASDAQ: BDRX) sets first EU enrollment for 4Q 2025 after EMA CTA approval - Stock Titan
Biodexa Pharmaceuticals (NASDAQ:BDRX) Stock Price Up 5.7% – Time to Buy? - Defense World
Biodexa Pharmaceuticals (NASDAQ:BDRX) Given Sell (E+) Rating at Weiss Ratings - Defense World
Why Did Biodexa Pharmaceuticals' Stock Drop After-Hours Despite Big Gain During Regular Trading? - inkl
Biodexa Hosts Breakfast Symposium on FAP Mechanisms and Chemoprevention at CGA‑IGC in October 2025 - Stock Titan
Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Short Interest Update - Defense World
Short Interest in Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Decreases By 53.3% - Defense World
Interim results for the six months ended June 30, 2025 - GlobeNewswire
Biodexa Pharmaceuticals reports 1H EPS (GBP0.0002) vs. (GBP0.001) last year - TipRanks
Biodexa says requirement for financing represents ‘material uncertainty’ - TipRanks
First Patients Enrolled: Biodexa's Breakthrough FAP Treatment Advances to Pivotal Phase 3 Trial with $35M Backing - Stock Titan
Biodexa begins phase 3 trial of FAP treatment with $20M funding By Investing.com - Investing.com South Africa
Biodexa begins phase 3 trial of FAP treatment with $20M funding - Investing.com Canada
$7 Billion Untapped Market: Biodexa's eRapa Could Be First FDA-Approved Drug for Devastating FAP Disease - Stock Titan
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Nanotechnology Stocks To Watch Today – September 1st - Defense World
Biodexa announces enrollment of first two patients in Phase 3 Serenta trial - MSN
Biodexa Pharmaceuticals (NASDAQ:BDRX) Trading 2.3% Higher – Time to Buy? - Defense World
Biodexa Announces Enrolment of First Patients into Pivotal - GlobeNewswire
[6-K] Biodexa Pharmaceuticals plc American Depositary Shs Current Report (Foreign Issuer) - Stock Titan
$7.3 Billion Market Opportunity: Biodexa's eRapa Could Become First-Ever Drug Treatment for FAP Cancer Risk - Stock Titan
Biodexa Pharmaceuticals (NASDAQ:BDRX) Cut to Strong Sell at Wall Street Zen - Defense World
Biodexa completes ADR ratio change to 1:100,000 ordinary shares By Investing.com - Investing.com South Africa
Biodexa Pharmaceuticals Implements ADR Ratio Change - TipRanks
ADR Ratio Change Effective | BDRX Stock News - GuruFocus
Biodexa completes ADR ratio change to 1:100,000 ordinary shares - Investing.com
Biodexa Pharmaceuticals PLC ADR ratio changes to 1:100,000. - AInvest
Biodexa Pharmaceuticals Announces ADR Ratio Change Effective July 31, 2025 - AInvest
ADR Ratio Change Effective - GlobeNewswire
Biodexa Implements Major ADR Restructuring: 10,000 to 100,000 Shares Per ADR Change Now Active - Stock Titan
Biodexa Pharmaceuticals (BDRX) Trading Halted with Pending News - GuruFocus
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):